193 related articles for article (PubMed ID: 29552177)
1. Improving immunotherapy for colorectal cancer using dendritic cells combined with anti-programmed death-ligand
Hu Z; Ma Y; Shang Z; Hu S; Liang K; Liang W; Xing X; Wang Y; Du X
Oncol Lett; 2018 Apr; 15(4):5345-5351. PubMed ID: 29552177
[TBL] [Abstract][Full Text] [Related]
2. Programmed Death-Ligand 1 on Antigen-presenting Cells Facilitates the Induction of Antigen-specific Cytotoxic T Lymphocytes: Application to Adoptive T-Cell Immunotherapy.
Goto T; Nishida T; Takagi E; Miyao K; Koyama D; Sakemura R; Hanajiri R; Watanabe K; Imahashi N; Terakura S; Murata M; Kiyoi H
J Immunother; 2016 Oct; 39(8):306-15. PubMed ID: 27548033
[TBL] [Abstract][Full Text] [Related]
3. A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy.
Takeda Y; Kataoka K; Yamagishi J; Ogawa S; Seya T; Matsumoto M
Cell Rep; 2017 May; 19(9):1874-1887. PubMed ID: 28564605
[TBL] [Abstract][Full Text] [Related]
4. A Novel Anti-PD-L1 Vaccine for Cancer Immunotherapy and Immunoprevention.
Chen J; Liu H; Jehng T; Li Y; Chen Z; Lee KD; Shen HT; Jones L; Huang XF; Chen SY
Cancers (Basel); 2019 Dec; 11(12):. PubMed ID: 31805690
[TBL] [Abstract][Full Text] [Related]
5. Dendritic cells engineered to secrete anti-DcR3 antibody augment cytotoxic T lymphocyte response against pancreatic cancer
Chen J; Guo XZ; Li HY; Zhao JJ; Xu WD
World J Gastroenterol; 2017 Feb; 23(5):817-829. PubMed ID: 28223726
[TBL] [Abstract][Full Text] [Related]
6. CD8
Farhood B; Najafi M; Mortezaee K
J Cell Physiol; 2019 Jun; 234(6):8509-8521. PubMed ID: 30520029
[TBL] [Abstract][Full Text] [Related]
7. Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro.
Blank C; Kuball J; Voelkl S; Wiendl H; Becker B; Walter B; Majdic O; Gajewski TF; Theobald M; Andreesen R; Mackensen A
Int J Cancer; 2006 Jul; 119(2):317-27. PubMed ID: 16482562
[TBL] [Abstract][Full Text] [Related]
8. A Novel PD-L1-Containing MSLN Targeting Vaccine for Lung Cancer Immunotherapy.
Zeng W; Pan J; Fang Z; Jia J; Zhang R; He M; Zhong H; He J; Yang X; Shi Y; Zhong B; Zeng J; Fu B; Huang M; Liu H
Front Immunol; 2022; 13():925217. PubMed ID: 35795680
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses.
Chen X; Pan X; Zhang W; Guo H; Cheng S; He Q; Yang B; Ding L
Acta Pharm Sin B; 2020 May; 10(5):723-733. PubMed ID: 32528824
[TBL] [Abstract][Full Text] [Related]
10. Application of PD-1 Blockade in Cancer Immunotherapy.
Wu X; Gu Z; Chen Y; Chen B; Chen W; Weng L; Liu X
Comput Struct Biotechnol J; 2019; 17():661-674. PubMed ID: 31205619
[TBL] [Abstract][Full Text] [Related]
11. Nafamostat mesilate, a serine protease inhibitor, suppresses interferon-gamma-induced up-regulation of programmed cell death ligand 1 in human cancer cells.
Homma S; Hayashi K; Yoshida K; Sagawa Y; Kamata Y; Ito M
Int Immunopharmacol; 2018 Jan; 54():39-45. PubMed ID: 29100036
[TBL] [Abstract][Full Text] [Related]
12. Lentivirus-mediated RNA interference targeting programmed death receptor ligand 1 increases the immunologic anti-tumor effect of dendritic cell vaccination against pancreatic cancer in SCID-hu mice.
Wang J; Sun M; Zhu X; Zhao H; Mao D; Zhang Z; Zhao X
Oncol Lett; 2019 Aug; 18(2):1539-1547. PubMed ID: 31423221
[TBL] [Abstract][Full Text] [Related]
13. Single Domain Antibody-Mediated Blockade of Programmed Death-Ligand 1 on Dendritic Cells Enhances CD8 T-cell Activation and Cytokine Production.
Broos K; Lecocq Q; Keersmaecker B; Raes G; Corthals J; Lion E; Thielemans K; Devoogdt N; Keyaerts M; Breckpot K
Vaccines (Basel); 2019 Aug; 7(3):. PubMed ID: 31394834
[TBL] [Abstract][Full Text] [Related]
14. Recent Progress in Dendritic Cell-Based Cancer Immunotherapy.
Matsuo K; Yoshie O; Kitahata K; Kamei M; Hara Y; Nakayama T
Cancers (Basel); 2021 May; 13(10):. PubMed ID: 34065346
[TBL] [Abstract][Full Text] [Related]
15. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant immunotherapy for cancer: both dendritic cell-priming and check-point inhibitor blockade are required for immunotherapy.
Seya T; Takeda Y; Takashima K; Yoshida S; Azuma M; Matsumoto M
Proc Jpn Acad Ser B Phys Biol Sci; 2018; 94(3):153-160. PubMed ID: 29526974
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity of lentivirus-mediated interleukin -12 gene modified dendritic cells in human lung cancer in vitro.
Ahmed Ali HA; Di J; Mei W; Zhang YC; Li Y; Du ZW; Zhang GZ
Asian Pac J Cancer Prev; 2014; 15(2):611-6. PubMed ID: 24568466
[TBL] [Abstract][Full Text] [Related]
18. Umbilical cord blood-derived CD11c(+) dendritic cells could serve as an alternative allogeneic source of dendritic cells for cancer immunotherapy.
Kumar J; Kale V; Limaye L
Stem Cell Res Ther; 2015 Sep; 6():184. PubMed ID: 26407613
[TBL] [Abstract][Full Text] [Related]
19. Expression of programmed death 1 ligands by murine T cells and APC.
Yamazaki T; Akiba H; Iwai H; Matsuda H; Aoki M; Tanno Y; Shin T; Tsuchiya H; Pardoll DM; Okumura K; Azuma M; Yagita H
J Immunol; 2002 Nov; 169(10):5538-45. PubMed ID: 12421930
[TBL] [Abstract][Full Text] [Related]
20. Contrasting Roles of the PD-1 Signaling Pathway in Dendritic Cell-Mediated Induction and Regulation of HIV-1-Specific Effector T Cell Functions.
Garcia-Bates TM; Palma ML; Shen C; Gambotto A; Macatangay BJC; Ferris RL; Rinaldo CR; Mailliard RB
J Virol; 2019 Mar; 93(5):. PubMed ID: 30541848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
